Results 41 to 50 of about 2,667 (184)

Establishment and Analysis ofSLC22A12(URAT1) Knockout Mouse

Nucleosides, Nucleotides and Nucleic Acids, 2010
In order to elucidate the mechanisms of post-exercise acute renal failure, one of the complications of hereditary renal hypouricemia, we have targeted the mouse Slc22a12 gene by the exchange of exons 1-4 with pMC1neo-polyA. The knockout mice revealed no gross anomalies.
M, Hosoyamada, Y, Takiue, H, Morisaki, J, Cheng, M, Ikawa, M, Okabe, T, Morisaki, K, Ichida, T, Hosoya, T, Shibasaki   +9 more
openaire   +3 more sources

Molecular analysis of the SLC22A12 (URAT1) gene in patients with primary gout [PDF]

Rheumatology, 2006
To analyse the SLC22A12 (URAT1) gene in primary gout patients, first-grade relatives and healthy controls and the possible association of them with demographic and clinical data.We included 69 consecutive patients with diagnosis of primary gout, as well as 29 first-grade relatives and 120 healthy volunteers.
J, Vázquez-Mellado, A L, Jiménez-Vaca, S, Cuevas-Covarrubias, V, Alvarado-Romano, G, Pozo-Molina, R, Burgos-Vargas   +5 more
openaire   +2 more sources

Antihyperuricemic Effects of Cornus officinalis Extract via URAT1 Regulation and Renoprotective Mechanisms. [PDF]

Int J Mol Sci
Hyperuricemia, characterized by elevated serum uric acid levels, is a major risk factor for gout and kidney disease. This study evaluated the antihyperuricemic effects of Cornus officinalis extract (COE) using urate transporter 1 (URAT1)-expressing ...
Sung YY, Kim DS, Kim SH, Yuk HJ.
europepmc   +2 more sources

Structural basis for the transport and substrate selection of human urate transporter 1

Cell Reports
Summary: High serum urate levels are the major risk factor for gout. URAT1, the primary transporter for urate absorption in the kidneys, is well known as an anti-hyperuricemia drug target.
Jingjing He, Guoyun Liu, Fang Kong, Qiulong Tan, Zhenzhou Wang, Meng Yang, Yonglin He, Xiaoxiao Jia, Chuangye Yan, Chao Wang, Hongwu Qian   +10 more
doaj   +1 more source

Saengmaeksan, a traditional herbal formulation consisting of Panax ginseng, ameliorates hyperuricemia by inhibiting xanthine oxidase activity and enhancing urate excretion in rats

Journal of Ginseng Research, 2021
Background: Saengmaeksan (SMS) is a traditional Korean medicine composed of three herbs, Panax ginseng, Schisandra chinensis, and Liriope platyphylla. SMS is used to treat respiratory and cardiovascular disorders.
Yoon-Young Sung, Heung Joo Yuk, Dong-Seon Kim   +2 more
doaj   +1 more source

Alpha-mangostin counteracts hyperuricemia and renal dysfunction by inhibiting URAT1 renal transporter in insulin resistance rat model

Beni-Suef University Journal of Basic and Applied Sciences, 2022
Background Alpha-mangostin (AM) has been shown to have hypoglycemic activity. This study aimed to analyze the effects of AM at a dose of 100 mg/kg and 200 mg/kg to alleviate hyperuricemia and renal dysfunction on high-fat/high-glucose diet and low dose ...
Vivian Soetikno, Andriyani Murwantara, Ahmad Aulia Jusuf, Melva Louisa   +3 more
doaj   +1 more source

Systematic Comparison of High‐Fat Diet– and Streptozotocin‐Induced Prediabetic Obese C57BL/6J Mouse Models: A Sex‐Based Protocol Optimization Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9897-9918, November 2026.
ABSTRACT Aims Animal models of prediabetes (Pre‐DM) are essential for studying metabolic disease and testing therapies, yet high‐fat diet (HFD) and HFD‐plus‐streptozotocin (STZ) protocols vary in feeding duration, STZ dose, and diagnostic criteria and rarely account for sex.
Min Xu, Chao Ke, Yangkun Liu, Wenying Shi, Yang Cao, Zhengyu Li, Yi Xiao, Wei Zhang   +7 more
wiley   +1 more source

Transcriptome-based reconstructions from the murine knockout suggest involvement of the urate transporter, URAT1 (slc22a12), in novel metabolic pathways [PDF]

, 2015
URAT1 (slc22a12) was identified as the transporter responsible for renal reabsorption of the medically important compound, uric acid. However, subsequent studies have indicated that other transporters make contributions to this process, and that URAT1 ...
Nigam, Sanjay K, Jamshidi, Neema, Eraly, Satish A, Liu, Henry C   +3 more
core   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, Volume 67, Issue 10, Page 5042-5074, October 2026.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study

Biomedicines, 2023
Chronic kidney disease (CKD) is a major global health problem for which there are no curative drug treatments. Hyperuricemia is one of risk factors for CKD.
Hidekatsu Yanai, Hisayuki Katsuyama, Mariko Hakoshima, Hiroki Adachi   +3 more
doaj   +1 more source